Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group
Drug Safety · 2026
DOI: 10.1007/s40264-025-01646-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Safety, 2026. Verfasst von Florence van Hunsel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, 's-Hertogenbosch, The Netherlands. f.vanhunsel@lareb.nl. Hauptthemen laut MEDLINE: Pharmacovigilance. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly, AbbVie, Bristol Myers Squibb, Alexion, CSL Behring, Roche, Celgene, Pfizer, Gilead, Novo Nordisk, Takeda, and Novartis.
Abstract (Originalsprache)
A focus group organised by the Drug Safety Research Unit (DSRU) International Working Group (IWG) on New Developments in Pharmacovigilance discussed current challenges and opportunities in pharmacovigilance (PV), emphasising the need for a multimodal approach in data analysis and accessibility of diverse data sources for drug safety surveillance. Nine participants, selected purposefully for their multisectoral expertise in PV, discussed the value of various data types, including data from clinical trials and real-world data (RWD), each offering distinct strengths and limitations. Key challenges identified included data standardisation, quality variability, technological barriers and ethical concerns, particularly with data derived from social media. Emerging tools such as knowledge graphs were highlighted for their potential to enhance data integration and signal detection, however further research is required. The group also addressed disparities in data access, with particular attention to regulatory restrictions, limited infrastructure in low-resource settings and restricted access to industry-held data. Proposed solutions included fostering greater data transparency, establishing secure data-sharing platforms and forming collaborative consortia to facilitate responsible and ethical data use. Overall, the discussion underscored the need for improved integration, access and methodological rigour to strengthen PV practices and enhance global drug safety monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH, 's-Hertogenbosch, The Netherlands. f.vanhunsel@lareb.nl.
- Department of PharmacoTherapy-Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands. f.vanhunsel@lareb.nl.
- Centre for Pharmacovigilance Sciences, Drug Safety Research Unit, Southampton, UK.
- School of Medicine, Pharmacy, and Biomedical Science, University of Portsmouth, Portsmouth, UK.
- RWE, Gilead Sciences, Uxbridge, UK.
- Merck KGaA, New York City, USA.
Förderung
- Eli Lilly, AbbVie, Bristol Myers Squibb, Alexion, CSL Behring, Roche, Celgene, Pfizer, Gilead, Novo Nordisk, Takeda, and Novartis
Zitieren
APA
van Hunsel, F., Lane, S., Cooper, D., Aurelius, T., Bobbins, A., Dickinson, H., Hauben, M., Morris, D., van Puijenbroek, E., Yeomans, A., Younus, M., & Shakir, S. (2026). Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group. Drug Safety. https://doi.org/10.1007/s40264-025-01646-2
Vancouver
van Hunsel F, Lane S, Cooper D, Aurelius T, Bobbins A, Dickinson H, et al. Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group. Drug Safety. 2026. doi:10.1007/s40264-025-01646-2
BibTeX
@article{vanHunsel2026,
author = {van Hunsel, Florence and Lane, Samantha and Cooper, Dawn and Aurelius, Taylor and Bobbins, Amy and Dickinson, Harriet and Hauben, Manfred and Morris, Denise and van Puijenbroek, Eugene and Yeomans, Alison and Younus, Manal and Shakir, Saad},
title = {Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group},
journal = {Drug Safety},
year = {2026},
doi = {10.1007/s40264-025-01646-2}
}
EUVIMED